33results about How to "Avoid systemic side effects" patented technology

Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions.

The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.

Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions.

A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.

The present invention comprises an all-natural composition of matter and methods of delivering nutrients, medicines, pain relievers, antioxidants, antidotes, antibiotics and various active ingredients and supplements directly to the affected area of the body. The all-natural carrier composition consists essentially of the combination of a natural oil, water, salt(s), natural emulsifier, natural sugar(s), plant extracts, natural acid(s), starch and natural flavor(s). The active substances that are mixed with the all-natural carrier composition, include, but are not limited to, drugs, vitamins, minerals, antibiotics anti-fungal agents, antioxidants, diuretics, allergy medicines, anti-inflammatory agents, muscle relaxers, pain reducers, diabetic drugs, neuropathy drugs, chemotherapy agents, arthritis drugs, lotions for eczema, shingles, psoriasis, skin rash; herbal medicines, erectile dysfunction drugs, hormones, cholesterol drugs, essential fatty acids, and the like. The all-natural carrier composition facilitates the penetration of active substances into the dermal layer of the skin.

Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, whereini) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations H310A, H433A and Y436A, orii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251D, L314D and L432D, oriii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251S, L314S and L432S.

Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first, the second, or the first and the second polypeptide comprise the mutation Y436A (numbering according to the EU index).

The invention relates to the field of drug carrier preparation, in particular to a gastric targeted drug carrier and a preparation method thereof. The gastric targeted drug carrier is prepared from the following raw materials: drug-containing emulsion and a crosslinking agent, wherein the drug-containing emulsion contains chitosan, chitosan quaternary ammonium salt and sodium glycerophosphate; and the crosslinking agent is used for crosslinking the emulsion into microspheres. The preparation method comprises the following steps: 1) preparing the drug-containing emulsion: with a aqueous solution of chitosan, chitosan quaternary ammonium salt and sodium glycerophosphate as an aqueous phase W, preparing the drug-containing emulsion with the aqueous phase, drugs and an oil phase containing anemulsifying agent; and 2) heating and stirring the drug-containing emulsion prepared in the step 1), crosslinking the chitosan quaternary ammonium salt and sodium glycerophosphate contained in the drug-containing emulsion to obtain gel microsphere suspension, heating the suspension and adding the crosslinking agent to carry out secondary crosslinking to solidify the gel microspheres. The drug carrier has the advantages of uniform and controllable grain size, high embedding rate and good dispersibility and simultaneously meets the requirements of the gastric targeted drug delivery carrier.